Document:

Asset Purchase Agreement

 EXHIBIT 4.14 
  
 ASSET PURCHASE AGREEMENT 
  
 THIS ASSET PURCHASE AGREEMENT (“Agreement”), is entered into as of February 23, 2005 by and between: 
  
 Unilens Corp. USA, a Delaware corporation with
offices at 10431 72nd Street North, Largo, Florida 33777, USA (“Buyer “), and, 
  
 CIBA Vision Corporation, a Delaware corporation with
offices at 11460 Johns Creek Parkway, Duluth, Georgia, USA (“Seller”). 
  
 Whereas, Seller desires to convey to Buyer and Buyer desires to acquire from Seller certain assets currently utilized by Buyer in its specialty contact lens business; 
  
 NOW, THEREFORE, in consideration of the obligations undertaken by each
party and other good and valuable consideration, and intending to be legally bound, the parties hereby agree as follows: 
  

	1.	DEFINITIONS 

  
 As used in this Agreement, the following terms shall have the meanings set forth below: 
  

	 	1.1.	“Affiliate” means any person or legal entity controlling, controlled by, or under common control with a party to this Agreement. 

  

	 	1.2.	“Assets” means the (i) Product Information (ii) Trademarks, (iii) Inventory, (iv) Product Registrations, and (v) Raw Material Information.

  

	 	1.3.	“Assumed Liabilities” means any and all liabilities of any kind, other than the Retained Liabilities, relating to the ownership, possession and/or use of the Assets
as of and following the Closing Date. 

  

	 	1.4.	“Bill of Sale” means the document attached hereto as Appendix C. 

  

	 	1.5.	“Closing Date” means the date on which consummation of the purchase and sale of the Assets and related transactions contemplated under this Agreement shall
occur. 

  

	 	1.6.	“Inventory” means the quantities of finished Products set forth in Schedule 1.5. 

  

	 	1.7.	“Inventory Purchase Price” means the amount payable by Buyer for the Inventory as determined in accordance with Section 4.2. 

 

	 	1.8.	“Net Sales” means the gross amounts billed for Products sold to third parties by Buyer or its Affiliates world wide, less: (i) allowances, credits, and adjustments
actually granted due to rejection or return of Products previously sold (ii) cash and trade discounts actually allowed; (iii) duties, tariffs and use taxes and other similar taxes incurred which are not invoiced to customers and which are allocated
in accordance with generally accepted accounting practices, and (iv) to the extent included in such bills, 

  

 113 

 charges for freight, shipping, and insurance. For purposes of this Agreement, all currencies will be
converted into US dollars by using the exchange rate quoted in the Wall Street Journal for the last day of the period for which the Net Sales is being calculated. 
  

	 	1.9.	“Products” means the contact lenses marketed by Seller under the brand names Aquaflex® and Softcon® EW. 

  

	 	1.10.	“Product Information” means: (i) designs, specifications, data and all documentation relating thereto, fitting guidelines, operating procedures, techniques,
processes, technical information, and manufacturing know-how, used or developed by Seller in connection with the manufacture of the Products, (ii) all customer lists, price lists, supplier lists, cost, sales and marketing data and similar
information related exclusively to the marketing and sale of any of the Products; and (iii) all advertising and marketing brochures and other materials relating exclusively to any of the Products. 

  

	 	1.11.	“Product Registrations” means all regulatory clearances, approvals and similar authorizations governing the manufacture, marketing and sale of
Products held by Seller as of the Closing Date, including, without limitation, pre-market approval applications (PMAs) and 501(k)s as set forth in Schedule 1.11. 

  

	 	1.12.	“Proscribed Activities” means the manufacturing, marketing, distribution, or sale of the Products under the Aquaflex® or Softcon® names. 

  

	 	1.13.	“Raw Material Information” means the formulation information, procedures, know-how, and regulatory approvals of Seller with respect to Tetrafilcon A.

  

	 	1.14.	“Retained Liabilities” means any and all liabilities of any kind relating to the ownership, possession, or use of the Assets prior to the Closing Date.

  

	 	1.15.	“Royalty Period” shall be five (5) years from the Closing Date. 

  

	 	1.16.	“Supply Agreement” means the agreement attached hereto as Appendix A. 

  

	 	1.17.	“Trademark Assignment” means the assignment of the Trademarks attached hereto as Appendix B 

  

	 	1.18.	“Trademarks” means all: (i) United States and foreign trademarks for the Products, whether registered or not, including, without limitation, U.S.
Registration Number 0983286 for Softcon®, U.S. Registration for Aquaflex®, and foreign registrations and the goodwill relating thereto; (ii) service marks, whether registered
of not, and the goodwill relating thereto; (iii) domain names; (iv) trade secrets; and (v) other intellectual property rights owned by Seller which relate to the Products. 

  

	 	1.19.	“Transaction Documents” means the Supply Agreement, the Bill of Sale, the Trademark Assignment and such other instruments of conveyance necessary to transfer
the Assets to Buyer. 

  

	2.	CONVEYANCE OF ASSETS 

  

	 	2.1.	Purchase and Sale. As of the Closing Date and upon the terms and subject to the conditions of this Agreement, Seller shall sell, assign, transfer, convey and deliver
to Buyer and Buyer shall purchase, acquire and accept, all right, title and interest of Seller in and to, the Assets. 

  

	 	2.2.	Delivery of Inventory. The Inventory shall be delivered F.O.B. Buyer’s facility located at 10431 72nd Street North, Largo, Florida. Seller shall assume all risk of loss or damage of any of the Inventory prior to delivery to Buyer’s facility and
Buyer’s acceptance of such Inventory. Seller shall deliver the Inventory to its designated carrier for shipment to Buyer within twenty four (24) hours following the Closing Date. 

  

 114 

	 	2.3.	No other Conveyance. Seller and Buyer expressly acknowledge and agree that, except for the Assets, no other tangible or intangible property or rights are intended or
shall be conveyed to Buyer pursuant to this Agreement. 

  

	 	2.4.	Further Assurances. From time to time after the Closing Date, at Buyer’s request and without further consideration, Seller will execute and deliver
such other and further instruments of conveyance, assignment and transfer, and take such other action, as Buyer may reasonably request, to provide for the effective conveyance and transfer of the Assets.  

  

	3.	ASSUMPTION OF LIABILITIES 

  

	 	3.5.	Assumption of Liabilities. As of the Closing Date, Buyer shall assume sole responsibility for any and all Assumed Liabilities. 

  

	 	3.6.	Retained Liabilities. Seller shall remain solely responsible for any and all Retained Liabilities. 

  

	4.	CONSIDERATION 

  

	 	4.1.	Buyer’s Obligations. In consideration for the conveyance of the Assets, Buyer shall: 

  

	 	4.1.1	Pay Seller the Inventory Purchase Price in accordance with Section 4.2. 

  

	 	4.1.2	Pay royalties to Seller in accordance with Section 4.3. 

  

	 	4.2.	Inventory Purchase Price. The Inventory Purchase Price shall be paid by Buyer as follows: 

  

	 	4.2.1	One Hundred Fifty Thousand US Dollars ($150,000), payable by wire transfer within twenty four (24) hours following the Closing Date. 

  

	 	4.2.2	Forty Percent (40%) of Net Sales derived from the sale of the Inventory payable by wire transfer forty-five (45) days following the close of each calendar quarter until total
payments made by Buyer pursuant to Paragraphs 4.2.1 and 4.2.2 equal Three Hundred Fifty Thousand US Dollars ($350,000). 

  

	 	4.3.	Royalties. Buyer shall pay Seller royalties on Net Sales of Products (excluding Net Sales from Products included in the Inventory) as set forth below:

  

	 	4.3.1	Royalty Rates. The applicable royalty rates shall be determined in accordance with Schedule 4.3.1. 

  

	 	4.3.2	Payments. Royalties shall be payable by wire transfer forty-five (45) days following the close of each calendar quarter. 

  

	 	4.4.	Reports, Records and Right to Review. Forty-five (45) days following the close of each calendar quarter during the Royalty Period, Buyer shall submit to Seller a
written report setting forth the Net Sales of Products sold by Buyer, including sales by Affiliates and licensees, and the calculation of the amount due and payable to Seller for such period. Buyer shall keep complete and accurate records of all
sales of Products, including any sales by Affiliates and licensees, for a period of two (2) years following the year in which the sales were made. Seller shall have the right on one (1) occasion each twelve-month period to have an independent
accountant from an internationally recognized accounting firm reasonably acceptable to Buyer have access to the records of Buyer during reasonable business hours for the purpose of verifying the amounts due Seller hereunder. Seller shall bear the
cost of any such review, provided however, if such review reflects that Buyer underpaid amounts due for the period under review by more than five percent (5%), then Buyer shall reimburse Seller for the reasonable fees and costs of such review.

  

 115 

	 	4.5.	Allocation of Consideration. Buyer and Seller agree that the foregoing consideration shall be allocated in a manner determined by mutual agreement of the parties. Each
party agrees to report the tax consequences of the transactions contemplated by this Agreement and the Transaction Documents in a manner consistent with this allocation and shall not take a position inconsistent therewith in connection with any
examination, investigation, refund claim, litigation or otherwise. 

  

	5.	SUPPLY AGREEMENT; ASSUMPTION OF CONTINUING OBLIGATIONS 

  

	 	5.1.	Supply Agreement. At Closing, Seller and Buyer shall enter into the Supply Agreement pursuant to which Seller shall manufacture and supply Softcon® EW contact lenses in accordance with the terms thereof
for a period not to exceed eighteen (18) months.  

  

	 	5.2.	Continuing Obligations. Except as provided in the Supply Agreement, Buyer shall, as of the Closing Date, assume sole responsibility for manufacturing,
marketing, sales and regulatory compliance, including product registrations and complaint handling relating to the Products as of the Closing Date. 

  

	 	5.3.	Returns. Seller shall remain solely responsible for processing any customer returns of Products sold by Seller prior to the Closing Date in accordance with
Seller’s returns policies. Buyer shall assume sole responsibility for any customer returns of Products sold by Buyer as of and following the Closing Date. 

  

	 	5.4.	Notice to Customers. The parties shall mutually agree on the content and coordinate the distribution of notices regarding the closing of this transaction to
Seller’s customer base for              the Products. After the Closing Date, Seller will advise its customer base (including all distributors of the Products) and all persons
requesting that Purchaser sell the Product to them, that the Assets have been sold to Buyer and that the Products are available from the Buyer. 

  

	 	5.5.	Non-Competition. Seller agrees that during the Royalty Period, Seller shall not, either directly or indirectly (including, without limitation, as a shareholder,
member, lender, joint venturer, partner, or consultant), whether within the United States or elsewhere engage in the Proscribed Activities; provided that Seller shall be permitted to fill any orders for Products received prior to the Closing Date.
Because Buyer would not have an adequate remedy at law to protect its business from any breach of the provisions of this Section 5.5, in the event of such a breach or threatened breach thereof by Seller, Buyer shall be entitled to injunctive
relief, in addition to such other remedies that would be available to Buyer. In the event of such breach, in addition to any other remedies, Buyer shall be entitled to receive from Seller payment of, or reimbursement for, its reasonable
attorneys’ fees and disbursements incurred in successfully enforcing such provision. 

  

	6.	REPRESENTATIONS AND WARRANTIES OF SELLER 

  
 Seller hereby represents and warrants to Buyer as follows: 
  

	 	6.1.	Corporate Status. Seller is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized and has all
requisite corporate power and authority to carry on its business as it is now being conducted, and to execute, deliver and perform this Agreement and each Transaction Document and to consummate the transactions contemplated hereby and thereby.

  

	 	6.2.	Consents and Approvals. The execution, delivery and performance of this Agreement, the Transaction Documents and the consummation of the transactions contemplated
hereby and thereby have been duly and validly authorized by all necessary corporate action on the part of Seller. This Agreement and each of the Transaction Documents have been duly and validly executed and delivered and constitute the legal, valid
and binding obligation of Seller, enforceable in accordance with their respective terms. 

  

 116 

	 	6.3.	Title to Assets. Seller has good and marketable title to all of the Assets, free and clear of any claims by third parties. 

  

	 	6.4.	Legal Proceedings and Disputes. To Seller’s knowledge, there are no pending or threatened legal actions, claims or proceedings against Seller that relate,
directly or indirectly, to the Assets. 

  

	 	6.5.	Compliance with Law. Seller is now and has heretofore been in compliance with all applicable laws, rules, regulations, orders and judgments of any governmental
authorities applicable to the Assets and has undertaken all action in accordance therewith required to be taken in connection with the sale of the Assets, including, without limitations, obtaining the authorization, consent and approval of all
relevant governmental entities. 

  

	 	6.6.	Trademarks. 

  

	 	6.6.1	Seller is the exclusive owner of the Trademarks and Seller has the right to assign the Trademarks to Buyer. 

  

	 	6.6.1.	Neither Seller nor any Affiliate of Seller has assigned, licensed or conveyed any rights or interest in the Trademarks that may be inconsistent with the rights granted to
Buyer hereunder. 

  

	 	6.6.2.	To the knowledge of the Seller, no third party is violating or infringing the Trademarks. 

  

	 	6.6.3.	To the extent that any of the Trademarks can be registered with a governmental agency, including, without limitation, the United States Patent & Trademark Office, such
Trademarks have be so registered and such registrations are in full force and effect. 

  

	 	6.7.	Taxes. All material tax returns and related information required to be filed by or on behalf of Seller relating to the Assets are true and correct in all material
respects and have been prepared and filed in accordance with applicable law. All taxes, interest, penalties, assessments and deficiencies relating to the Assets have been paid in full. To the knowledge of Seller, there are no unresolved claims
concerning any tax liability relating to the Assets as of the Closing Date. 

  

	 	6.8.	Inventory. To the knowledge of Seller, each Product included in the Inventory has been manufactured, packaged and labeled in accordance with all applicable laws, rules
and regulations and conforms to Seller’s quality standards and manufacturing specifications. 

  

	 	6.9.	Disclosure. No representation or warranty by Seller in this Agreement, nor any statement, document, or schedule delivered by Seller in connection with the transactions
contemplated by this Agreement shall contain any untrue statement of a material fact or omit a material fact necessary to make the statements contained therein not misleading. 

  

	 	6.10.	Disclaimer and Limitation of Liability. EXCEPT AS SET FORTH IN THIS ARTICLE 6, (i) SELLER MAKES NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, RELATING TO THE
ASSETS OF THE BUSINESS, INCLUDING WITHOUT LIMITATION, ANY REPRESENTATION OR WARRANTY AS TO VALUE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR FOR ORDINARY PURPOSES, OR ANY OTHER MATTER; AND (ii) THE ASSETS AND BUSINESS ARE CONVEYED TO BUYER
ON AN “AS IS, WHERE IS” BASIS AS OF THE DATE OF TITLE TRANSFER AND BUYER SHALL RELY ON ITS OWN EXAMINATION THEREOF. IN NO EVENT SHALL SELLER BE LIABLE FOR ANY MATTER WHATSOEVER RELATING TO THE USE OF THE ASSETS OR CONDUCT OF THE BUSINESS
FOLLOWING THE CLOSING DATE BY BUYER, ITS AFFILIATES OR ANY THIRD PARTY. IN NO EVENT SHALL SELLER BE LIABLE FOR INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OR LOST PROFITS. 

  

 117 

	 	6.11.	Not Bulk Sale. The sale of the Assets does not constitute a sale of more than half of the Seller’s inventory, as measured by value on the date of this
Agreement, and, after the sale of the Assets to Buyer, the Seller will continue to operate the same or similar kind of business after the sale as it operated prior to such sale.  

  

	7.	REPRESENTATIONS AND WARRANTIES OF BUYER 

  
 As a material inducement to Seller entering into this Agreement and consummating the transactions contemplated hereby, Buyer hereby represents and
warrants to Seller as follows: 
  

	 	7.1.	Corporate Status. Buyer is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized and has all
requisite corporate power and authority to carry on its business as it is now being conducted, and to execute, deliver and perform this Agreement and all Transaction Documents and to consummate the transactions contemplated hereby.

  

	 	7.2.	Consents and Approvals. The execution, delivery and performance of this Agreement, the Transaction Documents and the consummation of the transactions contemplated
hereby have been duly and validly authorized by all necessary corporate action on the part of Buyer. This Agreement and each of the Transaction Documents shall constitute the legal, valid and binding obligation of Buyer and shall be enforceable in
accordance with its terms. 

  

	 	7.3.	Disclosure. No representation or warranty by Buyer in this Agreement shall, as of the Closing Date, contain any untrue statement of a material fact or omit a material
fact necessary to make the statements contained therein not misleading. 

  

	8.	CLOSING; CONDITIONS PRECEDENT 

  

	 	8.1.	Closing. The closing of the transactions contemplated by this Agreement shall take place at the offices of Seller in Duluth, Georgia no later than February
28, 2005, or such other time or place as shall be mutually agreed upon by the parties. 

  

	 	8.2.	Conditions to Obligations of Buyer. The obligations of Buyer hereunder are subject to the satisfaction on and as of the Closing Date of each of the following
conditions: 

  

	 	8.2.1.	Representations and Warranties. The representations and warranties of Seller set forth in this Agreement shall be true and correct as of the Closing Date.

  

	 	8.2.2.	Performance of Obligations of Seller. Seller shall have performed or complied in all material respects with all obligations, conditions and covenants required to be
performed by it under this Agreement at or prior to the Closing Date. 

  

	 	8.2.3.	Deliveries. Seller shall have executed and delivered to Buyer the Supply Agreement, the Bill of Sale, the Trademark Assignment, and all Product Registrations.

  

	 	8.3.	Conditions to the Obligations of Seller. The obligations of Seller to sell, assign, convey, and the Assets are subject to the satisfaction on and as of the Closing
Date of each of the following conditions: 

  

	 	8.3.1.	Representations and Warranties. The representations and warranties of Buyer set forth in this Agreement shall be true and correct in all material respects as of the
Closing Date. 

  

 118 

	 	8.3.2.	Performance of Obligations of Buyer. Buyer shall have performed in all material respects all obligations required to be performed by it under this Agreement at or
prior to the Closing Date. 

  

	 	8.4.	Pre-Market Approval Applications. Seller shall supply Buyer with a signed copy of the notification of change of PMA ownership as filed with the United States Food and
Drug Administration for all PMAs as set forth in Schedule 1.11. 

  

	9.	SURVIVAL; INDEMNIFICATION 

  

	 	9.1	Survival. Each of the representations, warranties, agreements, covenants and obligations herein or in any schedule, exhibit, certificate or financial statement delivered by
any party to the other party incident to the transactions contemplated shall survive the Closing regardless of any investigation and shall not merge in the performance of any obligation by either party hereto. 

  

	 	9.2.	Seller Indemnification. From and after the Closing Date, to the extent provided in this Article 9, Seller shall indemnify and hold harmless Buyer and its
Affiliates, directors, officers, employees and agents (the “Seller Indemnified Parties”) from and against any (i) losses, damages, judgments, awards, penalties and settlements; (ii) demands, claims, suits, actions, causes of action,
proceedings and assessments; and (iii) costs and expenses, penalties, court costs and reasonable fees and expenses of attorneys and expert witnesses reasonably and necessarily incurred by a Seller Indemnified Party (collectively, “Losses”)
resulting from, arising out of or relating to any Retained Liability or any breach of any representation, warranty, covenant or agreement of Seller contained herein or in any Transaction Document. 

  

	 	9.3.	Buyer Indemnification. From and after the Closing Date, to the extent provided in this Article 9, Buyer shall indemnify and hold harmless Seller and each
Affiliate and agent of Seller (the “Buyer Indemnified Parties”) from and against any Losses resulting from, arising out of or relating to any Assumed Liability or any breach of any representation, warranty, covenant or agreement of
Buyer contained herein and in any Transaction Document. 

  

	 	9.4.	Limitation of Indemnification. Notwithstanding any provision of this Agreement to the contrary, the rights of an Indemnified Party and obligations of the other
party (the “Indemnifying Party”), respectively, under Sections 9.2 and 9.3 shall be limited as follows: 

  

	 	9.4.1.	All claims for indemnification by an Indemnified Party must be asserted no later than two (2) years after the Closing Date. 

  

	 	9.4.2.	No claim shall be made against an Indemnified Party unless and until the aggregate amount of such claims exceeds Twenty Five Thousand Dollars ($25,000), in which event the
Indemnified Party may claim indemnification for the amount in excess of Twenty Five Thousand Dollars ($25,000). 

  

	 	9.4.3.	The maximum aggregate liability of the Indemnifying Party shall be limited to the aggregate consideration paid by Buyer to Seller under Section 4.1 as of the date such claim
is made, reduced by the amount of any insurance proceeds, third party reimbursement or other compensation received by the Indemnifying Party and amounts previously paid by the Indemnifying Party pursuant to this Article 9.

  

	 	9.4.4.	In no event shall an Indemnifying Party be held responsible for indirect, consequential or other speculative damages. 

  

 119 

	 	9.5.	Procedure for Claims. In the event that an Indemnified Party receives notice of, or becomes aware of, a claim for which the Indemnified Party intends to
seek indemnity hereunder, the Indemnified Party shall promptly provide the Indemnifying Party with notice of such claim. The Indemnifying Party shall have the right, at its option and its own expense, to be represented by counsel of
its own choice and to defend against, negotiate, settle or otherwise deal with any such claim; provided, however, that the Indemnifying Party’s right to defend any such action or claim shall be conditioned upon such Indemnifying Party providing
the Indemnified Party with written notice; provided, further, that the Indemnifying Party shall not enter into any settlement or compromise of any such claim without the Indemnified Party’s prior written consent, which consent shall not be
unreasonably withheld. The Indemnified Party may participate in the defense of any claim with counsel of its own choice and at its own expense. The parties agree to cooperate fully with each other in connection with the defense, negotiation or
settlement of any such claim. In the event that the Indemnifying Party does not undertake the defense, compromise or settlement of a claim, the Indemnified Party shall have the right to control the defense or settlement of such Claim with counsel of
its choosing provided, however, that the Indemnified Party shall not settle or compromise any such claim without the Indemnifying Party’s prior written consent, which consent shall not be unreasonably withheld. 

  

	 	9.6.	Exclusive Remedy. The indemnification provided pursuant to this Article 9 shall be the sole and exclusive remedy for any claims for indemnification with respect
to breaches of representation and warranty in this Agreement and in each Transaction Document. 

  

	10.	TRANSACTION COSTS 

  

	 	10.1.	Transfer Taxes. Buyer shall be responsible for the payment of all transfer and all documentary stamp taxes, if any, and Seller shall be responsible for the payment of
any sales, use and similar taxes and fees arising from the sale of the Assets pursuant to this Agreement, if any. 

  

	 	10.2.	Transaction Costs. Each party shall be responsible for its own costs and expenses incurred in connection with the preparation, negotiation and consummation of this
Agreement and the Transaction Documents, including but not limited to attorney and other professional fees. 

  

	 	10.3.	Brokerage. The parties hereby expressly warrant and represent that neither party has any liability for payment to any broker, agent, or finder in connection with the
transactions contemplated under this Agreement and shall indemnify and hold harmless the other party hereto for such payments. 

  

	11.	TERMINATION 

  

	 	11.1	Termination Rights. This Agreement may be terminated by written notice before Closing: 

  

	 	(i)	by Buyer if any of the conditions set forth in Section 8.2 is not satisfied at the time scheduled for Closing or if the satisfaction of any such condition is or
becomes impossible, or 

  

	 	(ii)	by Seller if any of the conditions set forth in Section 8.3 is not satisfied at the time scheduled for Closing or if the satisfaction of any such condition is or becomes
impossible; 

  

	 	(ii)	by either party in the event the Closing does not occur, for any reason, prior to March 1, 2005. 

  

	 	11.2	Effect of Termination. In the event this Agreement is terminated pursuant to Section 11.1, Buyer shall (i) return any Products received from Seller pursuant to this
Agreement prior to or following 

  

 120 

 such termination; and (ii) return or destroy all documents containing the confidential information of
Seller and Buyer shall remain bound by the confidentiality obligations set forth in that certain Confidentiality Agreement dated December 2, 2004, which shall survive the termination of this Agreement for a period of five (5) years. 
  

	12.	MISCELLANEOUS 

  

	 	12.1.	Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when
one or more counterparts have been signed by each of the Parties and delivered to the other party. 

  

	 	12.2.	Entire Agreement. This Agreement, the exhibits and schedules hereto and the Transaction Documents contain the entire agreement between the parties with respect to the
subject matter hereof and supersede all previous agreements, negotiations, discussions, writings, understandings, commitments and conversations with respect to such subject matter. 

  

	 	12.3.	Amendments and Waivers. No provisions of this Agreement shall be deemed waived, amended, supplemented or modified by any party, unless such waiver, amendment,
supplement or modification is in writing and signed by the authorized representative of the party against whom it is sought to be enforced. 

  

	 	12.4.	Governing Law. This Agreement shall be governed by and construed and interpreted in accordance with the laws of the State of Georgia, irrespective of its choice of
laws principles, as to all matters, including matters of validity, construction, effect, enforceability, performance and remedies, and, to the extent applicable, the federal laws of the United States. 

  

	 	12.5.	Assignability. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and thereto, respectively, and their respective successors and
assigns. No party may assign its respective rights or delegate its respective obligations under this Agreement without the express prior written consent of the other party, which consent shall not be unreasonably withheld. 

 

	 	12.6.	Third Party Beneficiaries. Except as expressly set forth herein, there are no third party beneficiaries of this Agreement, and the provisions of this Agreement are
solely for the benefit of the parties and are not intended to confer any rights or remedies to any person which is not a party to this Agreement. 

  

	 	12.7.	Notices. All notices and other communications hereunder shall be in writing and shall be deemed duly given (a) on the date of delivery if delivered personally, (b) on
the third business day following the date of dispatch if delivered by an internationally recognized express courier service. All notices hereunder shall be addressed as follows: 

  
 If to Buyer, to: 
  
 Unilens Corporation 
 10431 72nd Street North 
 Largo, Florida 33777 
 Attention: Chief Financial Officer 
  
 If to Seller, to: 
  
 CIBA Vision Corporation 
 11460 Johns Creek Parkway 
 Duluth, Georgia, 30097 
 Attention: General Counsel 
  

 121 

 Any party may, by notice to the other party given in the form specified in this Section 12.7,
change the address to which such notices are to be given. 
  

	 	12.8.	Severability. If any provision of this Agreement is determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions
hereof shall remain in full force and effect and shall in no way be affected, impaired or invalidated thereby, so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner adverse to any party and
the parties shall negotiate in good faith in an effort to agree upon a suitable and equitable means to effect the original intent of the parties. 

  

	 	12.9.	Force Majeure. No party shall be deemed in default of this Agreement to the extent that any delay or failure in the performance of its obligations under this Agreement
results from any cause beyond its reasonable control and without its fault or negligence, such as acts of God, acts of civil or military authority, acts of terrorism, embargoes, epidemics, war, riots, insurrections, fires, explosions, earthquakes,
floods, unusually severe weather conditions, labor problems or unavailability of parts, or, in the case of computer systems, any failure in electrical or air conditioning equipment. In the event of any such excused delay, the time for performance
shall be extended for a period equal to the time lost by reason of the delay. 

  

	 	12.10.	Headings. The article, section and paragraph headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. 

  

	 	12.11.	Schedules and Appendices. All schedules and appendices referenced in this Agreement and attached hereto are incorporated herein by reference and shall be considered
for all purposes as part of this Agreement. 

  

	 	12.12.	Remedies. The Parties acknowledge that the legal remedy for breach by any of them of their respective obligations hereunder may be inadequate and, therefore, in
the event of any actual or threatened breach of any such obligation, such parties agree that, in addition to any other available remedy, such obligation may be specifically enforced against them. 

  

	 	12.13.	Waivers of Default. Waiver by either party of any default by the other party of any provision of this Agreement shall not be deemed a waiver by the waiving party of
any subsequent or other default, nor shall it prejudice the rights of the other party. 

  

	 	12.14.	Public Announcements. Neither party shall issue any press release or other public announcement concerning the transactions contemplated by this agreement without the
prior written consent of both the Seller and Buyer, which consent shall not be unreasonably withheld. Notwithstanding the foregoing, either party may make any required filings and disclosures pursuant to any applicable rules or requirements of the
United States Securities and Exchange Commission, or any other regulatory agency, or any exchange, without the prior written consent of the other party. 

  

 122 

 IN WITNESS WHEREOF, the Parties, intending to be bound hereby, have executed this Agreement as of the
Closing Date. 
  

			
	SELLER:
	
	CIBA VISION CORPORATION
		
	By:	 	 /s/ Stephen Osbaldeston

	Title:	 	 President, Global Specialty Lens & Lens Care Business

	
	BUYER:
	
	UNILENS CORP., USA
		
	By:	 	 /s/ Michael J. Pecora

	Title:	 	 Chief Financial Officer

  

 123 

 SCHEDULE 1.5 
  
 Inventory 
  

 124 

 SCHEDULE 1.11 
  
 Pre-Market Approval Applications (PMAs) and 501(k)s 
  
 PMA P880101 AQUAFLEX (Tetrafilcon A) 
  
 PMA P820021, limited solely to SOFTCON Aphakic, (Vifilcon A) 
  

 125 

 SCHEDULE 4.3.1. 
  
 Royalty Rates 
  

					
	 Product Sales

	  	Years (from Closing Date)

	  	Applicable % of Net Sales

	 Aquaflex
	  	1 through 3	  	8%
	 Aquaflex
	  	4 through 5	  	5%
	 SoftCon
	  	1 through 5	  	5%

  

 126 

 APPENDIX A 
  
 SUPPLY AGREEMENT 
  
 THIS AGREEMENT shall be effective as of February 23, 2005 (the “Effective Date”), by and between CIBA Vision Corporation, with its
principal offices at 11460 Johns Creek Parkway, Duluth, Georgia 30097 (“CIBA”), and Unilens Corp. USA, a Delaware corporation with offices at 10431 72nd Street North, Largo, Florida 33777 (“UNILENS”). 
  
 WHEREAS, UNILENS desires to purchase from CIBA and CIBA is willing and able to manufacture and supply UNILENS with certain contact lens products
under the terms and conditions described in this Agreement; 
  
 NOW, THEREFORE, UNILENS and CIBA agree as follows: 
  

	1.	DEFINITIONS 

  
 The following terms shall have the meaning specified in this Section: 
  

	 	1.1	“Affiliate” means any person or legal entity controlling, controlled by, or under common control with a party to this Agreement.

  

	 	1.2	“Confidential Information” shall mean the terms of this Agreement and any information of a confidential and proprietary nature disclosed by either party to
the other party in connection with this Agreement, including, but not limited to, technical, financial or commercial data, business plans and other competitively sensitive information. 

  

	 	1.3	“Facility” shall mean CIBA existing manufacturing facility located in Cidra, Puerto Rico, provided that CIBA shall have the right to relocate production to
an alternate CIBA manufacturing site upon written notice to UNILENS and any such site shall thereafter be the Facility for purposes of this Agreement. 

  

	 	1.4	“FDA” shall mean the United States Food and Drug Administration. 

  

	 	1.5	“FDCA” shall mean the United States Federal Food, Drug and Cosmetic Act, as amended. 

  

	 	1.6	“Firm Orders” shall mean irrevocable, written purchase orders for Products, which specify the (i) Product(s), by SKU, (ii) quantity to be delivered, (iii) ship to
location, (iv) designated carrier and (v) requested delivery date.  

  

	 	1.7	“Master Artwork Text” shall mean the specific text for all items of labeling, including, but not limited to all packaging, labels and markings to be utilized by
CIBA in connection with the manufacture of the Product. 

  

	 	1.8	“Order Date” will be the date that CIBA receives a Firm Order. 

  

	 	1.9	“Product” shall mean a Softcon® EW contact lens.  

  

	 	1.10	“Product Registrations” shall mean all regulatory clearances, approvals, or registrations under the FDCA, the Canadian Medical Device Regulations, the requirements
and standards applicable to CE marked products as described in the Medical Device Directive (EEC 93/42), or similar laws or regulations governing the marketing and sale of the Product. 

  

 127 

	 	1.11	“QSRs” shall mean the regulations promulgated under the FDCA, the requirements set forth in the Canadian Medical Device Regulations, and the requirements and
standards applicable to CE marked products as described in the Medical Device Directive (EEC93/42), as such laws may be amended from time to time. 

  

	 	1.12	“SKU” shall mean such stock keeping units for the Products as shall be mutually agreed upon by the parties. 

  

	 	1.13	“Specifications” shall mean the descriptions, criteria, standards, and other requirements set forth in the attached Appendix A. 

  

	 	1.14	“Unit” shall mean a single Product for which all operations set forth in Appendix A have been completed, packaged in a labeled vial.

  

	2.	MANUFACTURE AND SUPPLY 

  
 CIBA shall manufacture and supply UNILENS with Products subject to the terms and conditions set forth in this Agreement. 
  

	3.	PRICE AND PAYMENT 

  

	 	3.1	The purchase price shall be Seven Dollars and Fifty Cents US ($7.50) per Unit. 

  

	 	3.2	CIBA shall submit an invoice for payment with each shipment of Product. Subject to the right of rejection set forth in Section 4.4, UNILENS shall pay all undisputed
invoices no later than 30 days from receipt of invoice. 

  

	4.	ORDERS, SHIPMENTS AND ACCEPTANCE 

  

	 	4.1	UNILENS may submit up to three Firm Orders per year no later than ninety (90) days prior to the specified delivery date. 

  

	 	4.2	Each Firm Order shall specify a quantity of no less than three thousand (3,000) Units per order, with no less than 15 Units per SKU. 

  

	 	4.3	CIBA shall be responsible for delivery of Products to UNILENS’ designated carrier. Shipping terms shall be FOB, the Facility. Title and risk of loss or damage to any
shipment shall pass to UNILENS upon delivery to UNILENS’ designated carrier. UNILENS shall be responsible for all freight and insurance fees.  

  

	 	4.4	UNILENS shall have thirty (30) days from the date of delivery to inspect the Product received and shall have the right to reject, by written notice, and return, at
CIBA’s expense, any Product which does not conform to the Firm Order or the Specifications. UNILENS shall receive a credit for any such nonconforming Product. Any Product not rejected prior to the expiration of the above referenced inspection
period shall be deemed accepted by UNILENS, provided that such acceptance of delivery shall not be deemed to impair UNILENS’ rights under Section 9.3. 

  

	 	4.5	CIBA shall use commercially reasonable efforts to deliver to UNILENS the amount of Product set forth in the Firm Orders within ninety (90) days of the Order Date.

  

 128 

	5.	MASTER ARTWORK TEXT AND QUALITY ASSURANCE 

  

	 	5.1	UNILENS shall have the regulatory responsibility for the design, manufacture, packaging and labeling of the Product under the QSRs. UNILENS shall develop and provide the
Master Artwork Text to CIBA sixty (60) days prior to the date specified for delivery of UNILENS’ initial Firm Order. The Master Artwork Text shall become incorporated as part of the Specifications and shall not be altered in any way by CIBA
without the prior written consent of UNILENS. 

  

	 	5.2	CIBA shall conduct quality testing on the Products prior to delivery to UNILENS in accordance with the Specifications and such other procedures which have been pre-approved
in writing by UNILENS. CIBA shall comply with the QSRs and shall deliver to UNILENS concurrently with each shipment a Certificate of Compliance stating that each lot has been produced in accordance therewith. CIBA shall retain all lot records for no
less than three (3) years following the expiration date for each manufacturing lot.  

  

	 	5.3	UNILENS shall have access to all manufacturing records and any lot samples within ten (10) days of any request therefore. UNILENS shall have the right, following ten (10)
days prior written notice, to conduct an annual on-site audit of the Facility and relevant records to verify that CIBA’s quality control system is effective and properly documented in accordance with the QSRs. 

 

	 	5.4	CIBA shall not materially change the manufacturing process or raw materials utilized for the production of the Product without the prior written consent of UNILENS.

  

	6.	REGULATORY APPROVALS 

  

	 	6.1	CIBA shall obtain and maintain all site licenses, registrations and other regulatory approvals which may be or become necessary to continue manufacture of the Products at the
Facility. 

  

	 	6.2	UNILENS shall obtain, maintain and hold in its own name all device registrations and other regulatory approvals, which may be or become necessary, as reasonably determined by
UNILENS, to enable UNILENS to market and resell the Products and shall create and maintain all technical documentation required by the QSRs. 

  

	7.	WARRANTY 

  

	 	7.1	CIBA hereby warrants that (i) the Facility is an FDA certified facility and satisfies all requirements of the QSRs; and (ii) all Products supplied to UNILENS hereunder shall
have been manufactured, quality tested and packaged in accordance with, and shall conform to, the Specifications, the QSRs and all other requirements set forth in this Agreement. 

  

	 	7.2	Except for the warranties set forth above, CIBA makes no other warranty of any kind with regard to Products whether express, arising by operation of law, or otherwise,
including without limitation any implied warranties of merchantability and fitness for a particular purpose. CIBA shall not in any circumstance be liable for indirect, incidental, consequential or other speculative damages. 

 

	8.	RECALLS, COMPLAINTS AND RETURNS 

  

	 	8.1	The parties shall immediately contact each other in the event that either party has any reason to believe that a recall of any Product may be necessary. UNILENS and CIBA
shall jointly confer and cooperate to resolve any issues with respect to a recall, including without limitation, the necessity of declaring the recall, the 

  

 129 

 manner in which the recall should be conducted and the duration of the recall. CIBA shall be responsible
for the costs of a recall or, and shall reimburse UNILENS for any costs reasonably incurred by UNILENS, in the event the recall is determined, by mutual agreement of the parties (or by an independent third party if the parties are unable to agree
upon the cause), to have been caused by a defect in the manufacture of the Product. UNILENS shall be responsible for the costs of a recall and shall reimburse CIBA for any costs reasonably incurred by CIBA, in the event a recall is determined, by
mutual agreement of the parties (or by an independent third party if the parties are unable to agree upon the cause), to have been primarily caused by any act or omission of UNILENS. 
  

	 	8.2	UNILENS shall establish and maintain an appropriate system for collecting market complaints, communicating market complaint information to CIBA, facilitating corrective
actions and product recalls. UNILENS will report all product or packaging related complaints to CIBA within thirty (30) days following receipt of the complaint. Any suspected adverse incident shall be reported to CIBA within five (5) business days
following receipt of the complaint. CIBA shall take appropriate investigative and, if necessary corrective action, as required by the QSRs and shall provide UNILENS with all relevant information relating to any such investigation and corrective
action. UNILENS shall be responsible, in consultation with CIBA, for reporting any adverse incident to the relevant regulatory authorities as required by the QSRs. 

  

	 	8.3	UNILENS shall be responsible for responding to inquiries or complaints concerning any Product and for the collection and processing of any Products returned by customers as
defective. In the event that UNILENS determines that any such Product does not conform to the Specifications, UNILENS shall return such Product to CIBA for evaluation. CIBA shall issue a credit to UNILENS for any such Product which is confirmed by
CIBA to be nonconforming. 

  

	9.	INDEMNIFICATION 

  

	 	9.1	CIBA Indemnification. CIBA shall indemnify and hold harmless UNILENS, its Affiliates, directors, officers, employees and agents (the “CIBA Indemnified
Parties”) from and against any (i) losses, damages, judgments, awards, penalties and settlements; (ii) demands, claims, suits, actions, causes of action, proceedings and assessments; and (iii) costs and expenses, penalties, court costs and
reasonable fees and expenses of attorneys and expert witnesses reasonably and necessarily incurred by a CIBA Indemnified Party (collectively, “Losses”) resulting from, arising out of or relating to any breach of any
representation, warranty, covenant or agreement of CIBA under this Agreement. 

  

	 	9.2	UNILENS Indemnification. UNILENS shall indemnify and hold harmless CIBA and each Affiliate and agent of CIBA (the “UNILENS Indemnified Parties”) from and
against any Losses resulting from, arising out of or relating to any breach of any representation, warranty, covenant or agreement of UNILENS under this Agreement. 

  

	 	9.3	Procedure for Claims. In the event that an Indemnified Party receives notice of, or becomes aware of, a claim for which the Indemnified Party intends to seek indemnity
hereunder, the Indemnified Party shall promptly provide the Indemnifying Party with notice of such claim. The Indemnifying Party shall have the right, at its option and its own expense, to be represented by counsel of its own choice and to defend
against, negotiate, settle or otherwise deal with any such claim; provided, however, that the Indemnifying Party’s right to defend any such action or claim shall be conditioned upon such Indemnifying Party providing the
Indemnified Party with written notice; provided, further, that the Indemnifying Party shall not enter into any settlement or compromise of any such claim without the Indemnified Party’s prior written consent, which consent shall not be
unreasonably withheld. The Indemnified Party may participate in the defense of any claim with counsel of its own choice and at its own expense. The parties agree to cooperate fully with each other in connection with the defense, negotiation or
settlement of any such claim. In the event that the Indemnifying Party does not undertake the defense, compromise or settlement of a claim, the Indemnified Party shall have the right to control the defense or settlement of such Claim with counsel of
its choosing provided, however, that the Indemnified Party shall not settle or compromise any such claim without the Indemnifying Party’s prior written consent, which consent shall not be unreasonably withheld. 

  

 130 

	10.	CONFIDENTIALITY AND ANNOUNCEMENTS 

  

	 	10.1	The terms of that certain Secrecy Agreement between the parties dated December 2, 2004 shall continue to apply throughout the term of this Agreement.

  

	 	10.2	Neither party shall make any press release or trade announcement relating to this Agreement, or otherwise disclose the terms of this Agreement, without the prior written
consent of the other party, except as required by a court of competent jurisdiction or pursuant to the disclosure requirements of a governmental agency. 

  

	11.	TERM AND TERMINATION 

  

	 	11.1	This Agreement will commence on the Effective Date and will continue in effect for a period of eighteen months unless terminated prior to expiration as provided in this
Article 11. 

  

	 	11.2	CIBA shall have the right to terminate this Agreement without cause at any time upon six (6) months prior written notice in the event of a merger, asset sale, facility shut
down or other corporate reorganization or restructuring effecting the ownership or CIBA’s continued operation of the Facility. 

  

	 	11.3	Either party may terminate this Agreement for failure of the other party (the “Defaulting Party”) to cure any noncompliance with any material term of this Agreement
within thirty (30) days following receipt of written notice from the non-Defaulting Party. Either party may terminate this Agreement immediately in the event of the other party’s bankruptcy or initiation of similar proceedings by or against
such party. 

  

	 	11.4	Any Product ordered prior to the effective date of termination shall be delivered by CIBA and paid for in full by UNILENS in accordance with the terms of this Agreement.

  

	 	11.5	Notwithstanding any termination of this Agreement, the provisions of Articles 8, 9, 10 and 11 shall survive the termination or expiration of this Agreement for a period of
five years. 

  

	12.	FORCE MAJEURE 

  
 Neither party shall be liable to the other for loss or damages for any default or delay attributable to any cause beyond the reasonable control of that
party, including, but not limited to an act of God, flood, fire, explosion, strike, war, acts of terrorism, r governmental action other regulatory enforcement action arising from any violation of law, rule or regulation by the party seeking the
protection of this provision. If such an event occurs, the party effected shall notify the other party and shall exercise diligent efforts to resume performance of its obligations as soon as possible. In the event the party effected is unable to
resume performance within sixty (60) days, the other party shall have the right to terminate this Agreement upon ten (10) days prior written notice. 
  

	13.	MISCELLANEOUS 

  

	 	13.1	Waiver. No waiver of any of the terms of this Agreement shall be effective unless made in writing and signed by an authorized representative of the party waiving its
rights hereunder. 

  

	 	13.2	No License. No license under any trademark, patent, copyright or other property right is granted under this Agreement except to the extent required for CIBA to perform
its obligations hereunder. 

  

	 	13.3	Governing Law. This Agreement shall be construed and enforced pursuant to the laws of the State of Georgia, disregarding any conflicts of laws provisions, as if the
Agreement were to be performed in its entirety in Georgia. 

  

 131 

	 	13.4	Independent Contractors. Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, employer-employee or joint venture relationship
between the parties. All activities by the parties hereunder shall be performed by them as independent contractors. Neither party shall incur any debts or make any commitments for the other party, except to the extent specifically provided herein.

  

	 	13.5	Assignment. This Agreement shall be binding upon and inure to the benefit of the parties, their successors and permitted assigns. Neither party may assign this
Agreement without the prior written consent of the non-assigning party, which consent shall not be unreasonably withheld, provided that this Agreement may be assigned by either party in the event that such party enters into any merger, sale of a
controlling stock interest, sale of assets or other business combination that results in a change of control, provided that the surviving entity to such business combination is reasonably acceptable to the other party and expressly assumes all of
the affected party’s obligations hereunder. 

  

	 	13.6	Notices. All notices hereunder shall be in writing and shall be considered delivered on the day of hand delivery, one day after delivery to a nationally recognized
overnight delivery service, charges prepaid, three days after being sent by registered or certified mail, postage prepaid to the address for such party first set forth above or to such other address as any party shall have specified by notice to the
other in accordance with this paragraph. 

  

	 	13.7	Entire Agreement/Modification/Counter Parts. The terms of this Agreement represent the entire agreement of the parties with respect to the subject matter herein and
shall not be modified or supplemented except in a written document duly executed by the parties. This Agreement shall prevail in the event of any inconsistencies between it and the terms of any purchase order, invoice or other form utilized by the
parties. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall be deemed one and the same instrument. 

  

 132 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective duly authorized
officers the day and year first above written. 
  

			
	CIBA VISION CORPORATION
		
	By:	 	 /s/ Stephen Osbaldeston

	Title:	 	 President, Global Specialty Lens & Lens Care Business

	
	UNILENS CORP., USA
		
	By:	 	 /s/ Michael J. Pecora

	Title:	 	 Chief Financial Officer

  

 133 

 APPENDIX A 
 PRODUCT SPECIFICATIONS 
  

 134 

 APPENDIX B 
  

TRADEMARK ASSIGNMENT 
  

 135 

 APPENDIX C 
  

BILL OF SALE 
  
 THIS BILL OF SALE (“Bill of Sale”) is entered into as of February 23, 2005, by and between Unilens Corp., USA (“Buyer”), and
CIBA Vision Corporation, a Delaware corporation (“Seller”) with reference to the following facts: 
  
 A. Buyer and Seller are parties to that certain Asset Purchase Agreement of even date herewith (the “Purchase Agreement”). 
  
 B. Pursuant to the Purchase Agreement, Seller has agreed to sell certain
assets to Buyer and Buyer has agreed to purchase such Assets and to assume certain liabilities. 
  
 NOW THEREFORE, in reliance upon the foregoing recitals and in consideration of the mutual covenants set forth herein and in the Purchase Agreement
and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows: 
  

	 	1.	Capitalized terms used herein and not otherwise defined shall have the meaning ascribed to such terms in the Purchase Agreement. 

  

	 	2.	In accordance with and subject to the terms and conditions set forth in the Purchase Agreement, Seller hereby sells, assigns, transfers, conveys and delivers to Buyer all of
Sellers’ rights, title and interests in and to the Assets and Buyer hereby purchases, acquires and accepts, all right, title and interest of Seller in and to, the Assets. 

  

	 	3.	In accordance with and subject to the terms and conditions set forth in the Purchase Agreement, Buyers hereby expressly assumes sole responsibility for any and all Assumed
Liabilities. 

  
 IN WITNESS WHEREOF, the
parties hereto have executed this Bill of Sale as of the date first set forth above. 
  

									
	CIBA VISION CORPORATION	 	 	 	UNILENS CORP., USA
					
	By:	 	 /s/ Stephen Osbaldeston

	 	 	 	By:	 	 /s/ Michael J. Pecora

	Name:	 	 Stephen Osbaldeston

	 	 	 	Name:	 	 Michael J. Pecora

	Title:	 	 President, Global Specialty Lens & Lens Care Business

	 	 	 	Title:	 	 Chief Financial Officer

  

 136Severance Compensation Agreement

 EXHIBIT 4.15 
  
 SEVERANCE COMPENSATION AGREEMENT 
  
 AGREEMENT, dated as of July 1, 2005, between UNILENS CORP. USA, a Delaware corporation, UNILENS VISION INC., a
Vancouver corporation (collectively, the “Company”), and MICHAEL PECORA (“Executive”). 
  
 W I T N E S S E T H : 
  
 WHEREAS, Executive is a key employee of the Company, holding the offices of Vice President and Chief Financial Officer, and has made, and is expected to
continue to make, a significant contribution to the performance and growth of the Company; 
  
 WHEREAS, the Company, as a publicly-traded corporation, may be the target of a tender offer and, in any event, the Board of Directors of the Company may, from time to time consider proposals for the merger of the
Company with a third party, the disposition of the Company’s assets or the acquisition by a third party of the Company’s common stock; 
  
 WHEREAS, the Board of Directors has determined that the uncertainty raised by the possibility of such transactions may distract or cause the departure of
its key employees to the detriment of the Company and its stockholders; 
  
 WHEREAS, the Board of Directors has determined that the continued service of Executive is in the best interest of the Company and its stockholders and, accordingly, wishes to assure such continued service by providing Executive with certain
rights as to compensation in the event of the occurrence of a transaction described above; and 
  
 WHEREAS, the Board of Directors believes that the grant of such rights to Executive shall help assure his continued employment and dedication to his duties 
  
 NOW, THEREFORE, in consideration of the mutual agreements set forth below, the parties agree as follows: 
  
 1. Definition of a Change-in Control. For purposes of this Agreement,
a “Change in-Control” shall be deemed to have occurred if (a) there shall be consummated (i) any consolidation or merger of the Company in which the Company is the continuing or surviving corporation or pursuant to which shares
of the Company’s Common Stock would be converted into cash, securities or other property, other than a merger of the Company in which the holders of its Common Stock immediately prior to the merger have substantially the same proportionate
ownership of common stock of the surviving corporation immediately after the merger, or (ii) any sale lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of the
Company, (b) the stockholders of the Company shall approve any plan or proposal for the liquidation or dissolution of the Company (iii) any other change in control of the Company of a nature that would be required to be reported in
response to Item 6(e) of Schedule 14A of Regulation 14A under the Exchange Act or any other event or transaction that is declared by resolution of the Company’s Board of Directors to be a Change in Control. 
  
 2. Executive’s Rights on a Change-in-Control. If a Change in
Control occurs: 
  
 2.1 the Company shall pay to Executive, in a
single lump sum payment made not later than 10 days after the date of any public announcement respecting such Change-in-Control by the Company or any other party involved therein (the “Change-in-Control Date”), an amount equal to two times
Executive’s annual salary in effect immediately prior to such change- in-control (Executive’s current annual salary is $84,000); and 
  
 2.2 Any UVI stock options then held by Executive which are not fully vested as of the Change in Control Date shall automatically become fully vested.

  

 137 

 The foregoing shall apply whether or not Executive’s employment with the Company continues after the
Change-in-Control Date. If, thereafter, Executive’s employment with the Company is terminated by the Company or by Executive, for any reason, with or without cause, or due to Executive’s death or physical or mental disability or
incapacity, in addition to any other payments or benefits to which Executive may then be entitled, the Company shall pay to Executive, to the extent then unpaid, and not later than 10 days after the date of such termination, (i) any amounts
earned by Executive through the Effective Date as salary or under any bonus program or arrangement involving Executive and (ii) all amounts then owed to Executive for expense reimbursement in accordance with the Company’s then effective
policies and procedures relating to expense reimbursement. 
  
 3.
Executive’s Rights Prior to a Change-in-Control. If, prior to the occurrence of a Change-in-Control, (i) the Company terminates Executive’s employment for any reason other than for cause (as defined in Section 4),
(ii) Executive dies or (iii) Executive, due to physical or mental disability or incapacity, is unable to substantially perform his duties to the Company for a period of 30 consecutive days or more, the Company shall pay to Executive, in a
single lump sum payment made not later than 10 days after the date of such termination, an amount equal to two times Executive’s annual salary in effect immediately prior to such termination. In addition, if Executive voluntarily terminates his
employment prior to a Change-in-Control, the Company shall pay Executive in a single lump sum payment made not later than 10 days after the effective date of his termination, an amount equal to three-fourths of Executive’s annual salary in
effect immediately prior to such termination. 
  
 4. Definition
of Cause. A termination of Executive’s employment shall be deemed to be for “cause” only if it is based on one or more of the following grounds: (i) Executive’s willful and repeated refusal, after written notice thereof,
to perform specific directives of the Company’s Chief Executive Officer, when such directives are consistent with law and the scope and nature of Executive’s duties and responsibilities to the Company, (ii) after written warning,
continuing neglect or willful misconduct in the performance of his duties, (iii) material breach of Sections 6, (iv) conviction for a felony or any other crime involving moral turpitude or fraud or (v) repeated drunkenness or illegal
use of drugs which interferes with the performance of his duties under this Agreement and which continues after a warning. 
  
 5. Term. The term of this Agreement shall commence on the date of this Agreement and shall continue until the occurrence of a Change-in-Control and
for one year thereafter. 
  
 6. Confidentiality.

  
 6.1 General. Executive agrees and acknowledges that, as
a result of his employment with the Company, (i) he shall necessarily become informed of, and have access to, confidential information of the Company, including, without limitation, trade secrets, marketing plans and information, pricing
information, identity of actual and prospective clients and customers, developments, inventions, processes, formulae, designs, know how and technology, whether in written, digital or other form (together, “Confidential Information”) and
(ii) all such Confidential Information, even though it may have been or may be developed or otherwise acquired by Executive, is the exclusive, valuable property of the Company to be held by Executive in a fiduciary capacity and solely for the
Company’s benefit. 
  
 6.2 Non-Disclosure. Executive
shall not at any time, either during or subsequent to his employment hereunder, reveal, report, publish, transfer or otherwise disclose to any person or other entity, or use, any of the Confidential Information, without the written consent of the
Company’s Chief Executive Officer or its Board of Directors, except for use on behalf of the Company in connection with its business, and except for such information that legally and legitimately is or becomes of general public knowledge from
authorized sources other than Executive or which Executive is required by law or judicial process to disclose (but only to the extent required to be so disclosed). 
  
 6.3 Return of Materials. On the termination of his employment for any reason, Executive shall promptly deliver to the
Company all material and media containing any Confidential Information which are in Executive’s possession or control. 
  
 6.4 Remedies and Survival. Because the Company would not have an adequate remedy at law to protect its business and its interest in its trade
secrets, proprietary or confidential information and similar 
  

 138 

 commercial assets from any breach of the provisions of this Section 6, it shall be entitled, in the event of such a
breach or threatened breach thereof by Executive, to injunctive relief, in addition to such other remedies and relief that would be available to the Company. In the event of such a breach, in addition to any other remedies, the Company shall be
entitled to receive from Executive payment of, or reimbursement for, its reasonable attorneys’ fees and disbursements incurred in enforcing any such provision. The provisions of Sections 6 and 11 shall survive any termination of this Agreement.

  
 7. Entire Agreement; Amendments; No Waivers. This
Agreement sets forth the entire understanding of the parties with respect to its subject matter and merges and supersedes all prior understandings of the parties with respect to its subject matter. No provision of this Agreement may be waived or
modified, in whole or in part, except by a writing signed by each of the parties. Failure of any party to enforce any provision of this Agreement shall not be construed as a waiver of its rights under such or any other provision. No waiver of any
provision of this Agreement in any instance shall be deemed to be a waiver of the same or any other provision in any other instance. 
  
 8. Communications. All notices, consents and other communications given under this Agreement shall be in writing and shall be deemed to have been
duly given (a) when delivered by hand or by FEDEX or a similar overnight courier to, (b) five days after being deposited in any United States post office enclosed in a postage prepaid registered or certified mail envelope addressed to, or
(c) when successfully transmitted by facsimile (with a confirming copy of such communication to be sent as provided in (a) or (b) above) to, the party for whom intended, at the address or facsimile number for such party set forth
below, or to such other address or facsimile number as may be furnished by such party by notice in the manner provided herein; provided, however, that any notice of change of address or facsimile number shall be effective only upon receipt.

  

			
	If to the Company:	 	If to Executive:
		
	Unilens	 	Mr. Michael Pecora
	10431 72nd Street North	 	10431 72nd Street North
	Largo, Florida 34647-1511	 	Largo, Florida 33777-1511
	Att.: Chief Executive Officer	 	Fax No.: (727) 545-1883
	Fax No.: (727) 545-1883	 	 

  
 9. Successors and
Assigns. This Agreement shall be binding on, enforceable against and inure to the benefit of, the parties and their respective successors and permitted assigns, and nothing herein is intended to confer any right, remedy or benefit upon any other
person. Neither party may assign its rights or delegate its obligations under this personal Agreement without the express written consent of the other, except that the Company may assign this Agreement to any successor to its business. 

 
 10. Governing Law. This Agreement shall in all respects be governed
by and construed in accordance with the laws of the State of Florida applicable to agreements made and fully to be performed in such state, without giving effect to conflicts of law principles. 
  
 11. Severability and Savings Clause. If any provision of this
Agreement is held to be invalid or unenforceable by any court or tribunal of competent jurisdiction, the remainder of this Agreement shall not be affected thereby, and such provision shall be carried out as nearly as possible according to its
original terms and intent to eliminate such invalidity or unenforceability. In this regard, the parties agree that the provisions of Section 6, including, without limitation, the scope of the territorial and time restrictions, are reasonable
and necessary to protect and preserve the Company’s legitimate interests. If the provisions of Section 6 are held by a court of competent jurisdiction to be in any respect unreasonable, then such court may reduce the territory or time to
which it pertains or otherwise modify such provisions to the extent necessary to render such provisions reasonable and enforceable. 
  
 12. Counterparts and Construction. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
  

 139 

 Headings used in this Agreement are for convenience only and shall not be used in the interpretation of this Agreement.
References to Sections are to the Sections of this Agreement. As used herein, the singular includes the plural and the masculine, feminine and neuter gender each includes the others where the context so indicates. 
  
 IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first set
forth above. 
  

			
	UNILENS CORP. USA
		
	By	 	 /s/ Alfred W. Vitale

	 	 	Alfred W. Vitale
	 	 	President
	
	UNILENS VISION INC.
		
	By	 	 /s/ Alfred W. Vitale

	 	 	Alfred W. Vitale
	 	 	Chief Executive Officer
		
	By	 	 /s/ Michael J. Pecora

	 	 	Michael J. Pecora
	 	 	Executive

  

 140

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}]]